TY - JOUR
T1 - Activation of nuclear receptors by prostaglandins
AU - Ide, Tomomi
AU - Egan, Karine
AU - Bell-Parikh, L. Chastine
AU - FitzGerald, Garret A.
N1 - Funding Information:
Dr. FitzGerald is the Robinette Professor of Cardiovascular Medicine and the Bobst Professor of Pharmacology. This work was supported by grants from the National Institutes of Health (HL 61364, HL 70128) and a National Research Fellowship Award (DK-09942 to LCB), a Banyu-Merck Fellowship Award in Cardiovascular Medicine (to TI) and the American Heart Association (0010064U to KE).
PY - 2003/6/15
Y1 - 2003/6/15
N2 - Deletion of membrane receptors for prostaglandins has revealed their importance in diverse biological systems. Some evidence has accrued to support the contention that they may also ligate nuclear receptors, particularly peroxisomal proliferator activator receptors (PPARs). This is most pronounced in the case of 15-deoxy PGJ2, a cyclopentanone derivative of PGJ 2 as a ligand for PPARγ. However, while this compound can ligate the PPAR, the quantities formed in vivo suggest that this is an unlikely endogenous ligand. Furthermore, biosynthesis is unaltered in murine atherosclerosis and other inflammatory and metabolic disorders where activation of this PPAR has been implicated. The suggestion that prostaglandins serve as endogenous ligands for nuclear receptors is presently configured on the use of synthetic compounds and immunoreactive quantitation of dubious validity. The application of quantitatively precise and sensitive physicochemical methodology will enhance experiments designed to address this hypothesis.
AB - Deletion of membrane receptors for prostaglandins has revealed their importance in diverse biological systems. Some evidence has accrued to support the contention that they may also ligate nuclear receptors, particularly peroxisomal proliferator activator receptors (PPARs). This is most pronounced in the case of 15-deoxy PGJ2, a cyclopentanone derivative of PGJ 2 as a ligand for PPARγ. However, while this compound can ligate the PPAR, the quantities formed in vivo suggest that this is an unlikely endogenous ligand. Furthermore, biosynthesis is unaltered in murine atherosclerosis and other inflammatory and metabolic disorders where activation of this PPAR has been implicated. The suggestion that prostaglandins serve as endogenous ligands for nuclear receptors is presently configured on the use of synthetic compounds and immunoreactive quantitation of dubious validity. The application of quantitatively precise and sensitive physicochemical methodology will enhance experiments designed to address this hypothesis.
UR - http://www.scopus.com/inward/record.url?scp=0142195899&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0142195899&partnerID=8YFLogxK
U2 - 10.1016/S0049-3848(03)00418-3
DO - 10.1016/S0049-3848(03)00418-3
M3 - Article
C2 - 14592554
AN - SCOPUS:0142195899
SN - 0049-3848
VL - 110
SP - 311
EP - 315
JO - Thrombosis Research
JF - Thrombosis Research
IS - 5-6
ER -